If you have been reading about analytical methods and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Further reading == Maheshwari, Saurabh; Ingole, Dilip; Chatterjee, Samar; Rajesh, Uddandam; Anand, Varun (2021). "A case report of achondrogenesis type II (Langer-Saldino achondrogenesis)". Egyptian Journal of Radiology and Nuclear Medicine. 52 (1) 113. doi:10.1186/s43055-021-00479-0. ISSN 2090-4762. Kobayashi, Yukari; Ito, Yuki; Taniguchi, Kosuke; Harada, Kana; Yamamura, Michihiro; Sato, Taisuke; Takahashi, Ken; Kawame, Hiroshi; Hata, Kenichiro; Samura, Osamu; Okamoto, Aikou (2022-11-15). "Novel missense COL2A1 variant in a fetus with achondrogenesis type II". Human Genome Variation. 9 (1). Springer Science and Business Media LLC: 40. doi:10.1038/s41439-022-00218-5. ISSN 2054-345X. PMC 9663423. PMID 36376277.
On 15 October, Hezbollah launched five anti-tank missiles towards northern Israel killing one civilian and injuring three others in Shtula. UNIFIL said that their headquarters in Naqoura in southern Lebanon was hit by rocket fire with no casualties reported. Lieutenant Amitai Granot, commander of the 75th Battalion of the IDF's Golan Brigade and son of Rabbi Tamir Granot, was killed in a missile attack on an IDF post bordering Lebanon. On 13 October, while a group of Reuters, AFP and Al Jazeera journalists were transmitting a live video feed of an IDF outpost in Aalma ech Chaab, two tank rounds fired directly hit the group. The first killed Reuters photojournalist Issam Abdallah. The second strike was much more powerful and ignited the Al Jazeera vehicle, a white Toyota, which Al Jazeera journalists Carmen Joukhadar and Elie Brakhya, as well as their AFP colleague Dylan Collins were standing next to. Reuters photographer Christina Assi was also critically injured. The Lebanese Army has said the IDF fired the missile that killed Abdallah. Another Reuters reporter at the scene said Abdallah was killed by projectiles fired from the direction of Israel. His last post on Instagram, posted a week before he was killed, was a photograph of Shireen Abu Akleh, a Palestinian journalist for Al Jazeera Arabic who had been killed by Israel in 2022. On 16 October, Amnesty International reported that the IDF fired white phosphorus shells into Dhayra, hospitalizing nine civilians and setting fire to civilian objects.
The radioactivity of all radioactive waste weakens with time. All radionuclides contained in the waste have a half-life—the time it takes for half of the atoms to decay into another nuclide. Eventually, all radioactive waste decays into non-radioactive elements (i.e., stable nuclides). Since radioactive decay follows the half-life rule, the rate of decay is inversely proportional to the duration of decay. In other words, the radiation from a long-lived isotope like iodine-129 will be much less intense than that of a short-lived isotope like iodine-131. The two tables show some of the major radioisotopes, their half-lives, and their radiation yield as a proportion of the yield of fission of uranium-235. The energy and the type of the ionizing radiation emitted by a radioactive substance are also important factors in determining its threat to humans. The chemical properties of the radioactive element will determine how mobile the substance is and how likely it is to spread into the environment and contaminate humans. This is further complicated by the fact that many radioisotopes do not decay immediately to a stable state but rather to radioactive decay products within a decay chain before ultimately reaching a stable state.
The average age of participants was 66 years and more participants were male (77%) than female. To determine the drug's effectiveness, investigators examined the occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits. Participants were randomly assigned to receive a once-daily dose of either 10 mg of dapagliflozin or a placebo (inactive treatment). After about 18 months, people who received dapagliflozin had fewer cardiovascular deaths, hospitalizations for heart failure, and urgent heart-failure visits than those receiving the placebo. In July 2020, the FDA granted AstraZeneca a Fast Track Designation in the US for the development of dapagliflozin to reduce the risk of hospitalization for heart failure or cardiovascular death in adults following a heart attack. In August 2020, detailed results from the Phase III DAPA-CKD trial reportedly showed that dapagliflozin on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease stages 2–4 and elevated urinary albumin excretion. The results were consistent in patients both with and without type 2 diabetes. In April 2021, the FDA expanded the indications for dapagliflozin to include reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.
Sources: en.wikipedia.org
== Prevalence and health effects == Lignans are the principal source of dietary phytoestrogens in typical Western diets, even though most research on phytoestrogen-rich diets has focused on soy isoflavones. Lignan's enterolignan products enterodiol and enterolactone have weak estrogenic activity, but they may also exert biological effects through non-estrogenic means. A 2021 review found that lignans have a positive effect on lipid profiles of patients with dyslipidemia related diseases. As of 2022, there is limited evidence that dietary intake of lignans is associated with a reduced cancer and cardiovascular disease risk.
Seizures Syndrome of inappropriate secretion of antidiuretic hormone Blood dyscrasias including: Agranulocytosis Thrombocytopenia Eosinophilia Leukopenia Myocardial infarction Heart block QTc interval prolongation Sudden cardiac death Depression worsening Suicidal ideation
In addition to these biomarkers, the FDA has approved certain drug-companion diagnostic pairings based on genetic mutations. For example, BRAF-targeted therapies for metastatic melanoma are only indicated for patients whose tumors harbor a BRAF mutation. While these tests are now commonly marketed as essential tools for precision oncology, they remain costly. Moreover, some have been the subject of controversy or misuse. Notable examples include the Duke University cancer fraud scandal and questionable claims surrounding so-called "liquid biopsies."
Sources: en.wikipedia.org
The tension of the chain that does the cutting is adjusted so that it neither binds on, nor comes loose from the guide bar. The tensioner is either operated by turning a screw or a manual wheel. The tensioner is either in a lateral position underneath the exhaust or integrated into the clutch cover. Lateral tensioners have the advantage that the clutch cover is easier to mount, but the disadvantage that it is more difficult to reach nearby the bar. Tensioners through the clutch cover are easier to operate, but the clutch cover is more difficult to attach. When turning the screw, a hook in a bar hole moves the bar either out (tensioning) or in, making the chain loose. Tension is correct when it can be moved easily by hand and is not loose on the bar. When tensioning, hold the bar nose up and pull the bar nuts tight. Otherwise, the chain might derail. The underside of each link features a small, metal finger called a "drive link", which locates the chain on the bar, helps to carry lubricating oil around the bar, and engages with the engine's drive sprocket inside the body of the saw. The engine drives the chain around the track by a centrifugal clutch, engaging the chain as engine speed increases under power, but allowing it to stop as the engine speed slows to idle speed. Consistent improvement to overall chainsaw design, including adding safety features, has taken place over the years. These include chain-brake systems, better chain design, and lighter, more ergonomic saws, including fatigue-reducing antivibration systems.
==== Partitioning ==== ParM: this protein forms dynamic filaments that push plasmid copies to opposite poles of the cell ParR: recruits ParM to the plasmid by acting as a DNA-binding protein that recognizes the ParC centromere-like site. ParC: the centromere-like site where ParR binds.
The amount of the unknown is determined from a standard curve. Nephelometry can be used to detect either antigen or antibody, but it is usually run with antibody as the reagent and the patient antigen as the unknown. In the Immunology Medical Lab, two types of tests can be run: "end point nephelometry" and "kinetic (rate) nephelometry". End point nephelometry tests are run by allowing the antibody/antigen reaction to run through to completion (until all of the present reagent antibodies and the present patient sample antigens that can aggregate have done so and no more complexes can form). However, the large particles will fall out of the solution and cause a false scatter reading, thus kinetic nephelometry was devised. In kinetic nephelometry, the rate of scatter is measured right after the reagent is added. As long as the reagent is constant the rate of change can be seen as directly related to the amount of antigen present.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.